Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Intercept hit hard as NASH trial misses the mark

Supreme court throws Novartis a lifeline for Gilenya defense

Frontiers Health Steering Committee spotlight: Eugene Borukhovich

Babylon hires Andrew Hine to spearhead overseas expansion

Merck defends blockbuster Januvia franchise from patent challenge

Symkevi

Lungs-16-9

Market Access/ News/ News

Vertex gets EU okay to treat younger cystic fibrosis patients

Phil Taylor cystic fibrosis, ema, Kalydeco, regulatory approval, Symkevi, Vertex Pharma 0 Comment

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to children as

X

Vertex gets EU okay to treat younger cystic fibrosis patients

https://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/

Market Access/ News/ News

Vertex and Alnylam orphan drugs set for EU approval

Piotr Wnuk Alnylam, CHMP, ivacaftor, Onpattro, Symkevi, Vertex 0 Comment

Orphan drugs for cystic fibrosis and the hereditary rare disease hATTR are on course for European approval after

X

Vertex and Alnylam orphan drugs set for EU approval

https://pharmaphorum.com/market-access-2/chmp-vertex-symkevi-alnylam-onpattro/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Name change for Johnson & Johnson offshoot to Kenvue
Getting approval will only be the first challenge facing lecanemab
Almirall joins IL-2 push in autoimmunity with $507m Simcere deal
FDA clears Dupixent as first drug for rare skin disorder
Novo Nordisk grabs NASH drug from Ventus in $703m deal

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com